MedPath

Sulindac

Generic Name
Sulindac
Drug Type
Small Molecule
Chemical Formula
C20H17FO3S
CAS Number
38194-50-2
Unique Ingredient Identifier
184SNS8VUH

Overview

Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.

Background

Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.

Indication

For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.

Associated Conditions

  • Ankylosing Spondylitis (AS)
  • Colorectal Adenomas
  • Gout
  • Osteoarthritis (OA)
  • Rheumatoid Arthritis
  • Tendonitis exacerbated
  • Acute Subacromial bursitis
  • Acute supraspinatus tendinitis

FDA Approved Products

Sulindac
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:200 mg in 1 1
Approved: 2019/04/22
NDC:50090-4976
SULINDAC
Manufacturer:Proficient Rx LP
Route:ORAL
Strength:200 mg in 1 1
Approved: 2022/03/01
NDC:71205-648
SULINDAC
Manufacturer:Major Pharmaceuticals
Route:ORAL
Strength:150 mg in 1 1
Approved: 2023/07/28
NDC:0904-7334
SULINDAC
Manufacturer:Major Pharmaceuticals
Route:ORAL
Strength:200 mg in 1 1
Approved: 2023/07/28
NDC:0904-7335
SULINDAC
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:200 mg in 1 1
Approved: 2022/01/27
NDC:71335-0413

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath